Eptifibatide can cause acute profound thrombocytopenia within hours of administration, highlighting the need for early platelet monitoring.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to possible rapid thrombocytopenia with eptifibatide; leaves open incidence and monitoring protocols in larger cohorts.
An 80-year-old woman and a 79-year-old man underwent urgent percutaneous coronary intervention and received adjunctive eptifibatide. Platelet counts in both patients fell to below 20 x 10(3)/mm3 within 4 hours of eptifibatide administration. Reports in the medical literature reinforce the importance of recognizing that eptifibatide can cause acute profound thrombocytopenia. All three available glycoprotein IIb-IIIa inhibitors--abciximab, eptifibatide, and tirofiban--have been associated with the development of this disorder. Thus, clinicians should routinely monitor platelet counts in patients receiving glycoprotein IIb-IIIa inhibitors within 2-4 hours of the start of the infusion.
No takes yet. Share an insight, caveat, or question.
Nagge et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: